Vanguard Group Inc. Purchases 210,755 Shares of Illumina, Inc. (NASDAQ:ILMN)

Vanguard Group Inc. grew its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 1.2% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 18,178,513 shares of the life sciences company’s stock after acquiring an additional 210,755 shares during the quarter. Vanguard Group Inc. owned about 0.11% of Illumina worth $2,531,176,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. VisionPoint Advisory Group LLC boosted its position in shares of Illumina by 344.6% during the 3rd quarter. VisionPoint Advisory Group LLC now owns 249 shares of the life sciences company’s stock valued at $34,000 after acquiring an additional 193 shares during the last quarter. Wetzel Investment Advisors Inc. bought a new position in shares of Illumina during the 4th quarter valued at approximately $37,000. Gradient Investments LLC boosted its position in shares of Illumina by 375.0% during the 4th quarter. Gradient Investments LLC now owns 285 shares of the life sciences company’s stock valued at $40,000 after acquiring an additional 225 shares during the last quarter. North Star Investment Management Corp. boosted its position in shares of Illumina by 183.0% during the 4th quarter. North Star Investment Management Corp. now owns 300 shares of the life sciences company’s stock valued at $42,000 after acquiring an additional 194 shares during the last quarter. Finally, MeadowBrook Investment Advisors LLC bought a new position in shares of Illumina during the 4th quarter valued at approximately $42,000. 89.42% of the stock is currently owned by institutional investors.

Illumina Stock Performance

Shares of Illumina stock opened at $109.07 on Tuesday. The firm has a market cap of $17.37 billion, a P/E ratio of -13.38 and a beta of 1.20. The company has a current ratio of 1.75, a quick ratio of 1.36 and a debt-to-equity ratio of 0.26. Illumina, Inc. has a 12 month low of $89.00 and a 12 month high of $203.19. The stock’s fifty day moving average price is $114.50 and its 200-day moving average price is $127.83.

Illumina (NASDAQ:ILMN) last posted its earnings results on Thursday, May 2nd. The life sciences company reported $0.09 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.04 by $0.05. Illumina had a positive return on equity of 2.31% and a negative net margin of 28.71%. The company had revenue of $1.08 billion for the quarter, compared to analyst estimates of $1.05 billion. During the same quarter in the previous year, the firm earned $0.08 earnings per share. The firm’s quarterly revenue was down 1.0% compared to the same quarter last year. On average, equities research analysts expect that Illumina, Inc. will post 1.04 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on ILMN. Scotiabank lowered their price target on Illumina from $185.00 to $176.00 and set a “sector outperform” rating for the company in a research report on Monday, May 6th. Royal Bank of Canada restated an “outperform” rating and issued a $253.00 price target on shares of Illumina in a research report on Tuesday, April 9th. Robert W. Baird raised their price target on Illumina from $125.00 to $128.00 and gave the stock a “neutral” rating in a research report on Friday, May 3rd. TD Cowen reduced their target price on Illumina from $140.00 to $122.00 and set a “hold” rating on the stock in a research note on Thursday, June 6th. Finally, Jefferies Financial Group assumed coverage on Illumina in a research note on Monday, June 3rd. They issued a “hold” rating and a $115.00 target price on the stock. Two equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat, Illumina presently has a consensus rating of “Hold” and an average price target of $158.14.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.